Sarcoma and other solid tumors

ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL)

Principal Investigator: Katherine Matthay, MD

 

ADVL1312: A Phase I/II Study of MK-1775 in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

Principal Investigator: Katherine Matthay, MD

 

ADVL1314: A Phase I Study of Eribulin Mesylate (E7389, Ind #116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (excluding CNS), including Lymphomas

Principal Investigator: Katherine Matthay, MD

 

ADVL1315: A Phase I Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib  in Children with Recurrent or Refractory Solid Tumors

Principal Investigator: Katherine Matthay, MD

 

ADVL1322: A Phase II Study of Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors

Principal Investigator: Amit Sabnis, MD, MS

 

ADVL1412: A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Principal Investigator: Katherine Matthay, MD

 

ADVL1414: A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors

Principal Investigator: Katherine Matthay, MD

 

ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

Principal Investigator: Katherine Matthay, MD

 

ADVL1522: A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND 126953,NSC 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Periperal Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

Principal Investigator: Katherine Matthay, MD

 

ARET12P1: A Multi-Institutional Feasibililty Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma

Principal Investigator: Katherine Matthay, MD

 

AOST1321: A Phase 2 Study of Denosumab (IND#127430, NSC#744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Principal Investigator: Robert Goldsby, MD

 

AOST 1521: A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND#128248, NSC#763737), in Recurrent or Refractory Osteosarcoma

Principal Investigator: Robert Goldsby, MD

 

GSK Trametinib: An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 mutation

Principal Investigator: Sabine Mueller, MD, PhD

 

IA Melphalan and Chemo: A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma

Principal Investigator: Anuradha Banerjee, MD, MPH

 

Ignyta Entrectinib: A Phase 1/1b. Open-Label, Dose-Escalation and Expannsion Study of Entrctinib in Children and Adolescents with Recurrent/Refactory Solid Tumors and Primary CNS Tumor

Principal Investigator: Amit Sabnis, MD

 

AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG479, NSC 750008, IND 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Principal Investigator: Robert Goldsby, MD

 

EZH102: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Principal Investigator: Kieuhoa Vo, MD